Lilisbeth Perestelo-Pérez1, Amado Rivero-Santana2, Mauro Boronat3, Juan A Sánchez-Afonso4, Jeanette Pérez-Ramos4, Victor M Montori5, Pedro Serrano-Aguilar6. 1. Evaluation Unit of the Canary Islands Health Service (SESCS), Tenerife, Spain; Health Services Research on Chronic Patients Network (REDISSEC), Spain; Center for Biomedical Research of the Canary Islands (CIBICAN), Tenerife, Spain. Electronic address: lperperr@gobiernodecanarias.org. 2. Health Services Research on Chronic Patients Network (REDISSEC), Spain; Center for Biomedical Research of the Canary Islands (CIBICAN), Tenerife, Spain; Canarian Islands Foundation of Health Research (FUNCANIS), Tenerife, Spain. 3. Division of Endocrinology and Nutrition, Insular University Hospital, Las Palmas de Gran Canaria, Spain. 4. Canarian Islands Foundation of Health Research (FUNCANIS), Tenerife, Spain. 5. Knowledge and Evaluation Research (KER) Unit, Mayo Clinic, Rochester, MN, USA; Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN, USA. 6. Evaluation Unit of the Canary Islands Health Service (SESCS), Tenerife, Spain; Health Services Research on Chronic Patients Network (REDISSEC), Spain; Center for Biomedical Research of the Canary Islands (CIBICAN), Tenerife, Spain.
Abstract
OBJECTIVE:Statin choice, an encounter decision aid (DA), was developed in the USA to facilitate shared decision making between patients and clinicians about the use of statins to reduce cardiovascular risk. We aimed to assess the efficacy of this DA, compared to usual primary care, in Spanish patients with type 2 diabetes. METHODS: Cluster randomized trial with 29 clinicians and 168 patients. Knowledge of statins, cardiovascular risk perception, decisional conflict, anxiety and satisfaction with the decision making process were assessed immediately after intervention, and self-reported adherence at three months. RESULTS: Intervention significantly improved knowledge (p=0.01), perception of the 10-year risk of myocardial infarction without (p=0.01) and with statins (p=0.08), and satisfaction (p=0.01). There were no significant differences in decisional conflict, anxiety, consultation time or adherence, although more intervention patients reported taking all pills during the last week (92.7% vs. 81%; p=0.19). CONCLUSION: The statin choice DA improved the quality of decision making about statins. PRACTICE IMPLICATIONS: This trial contributes to the body of evidence substantiating the efficacy of statin choice and extending it to Spanish clinicians and their patients with type 2 diabetes. TRIAL REGISTRATION: This trial is registered with the European Union Clinical Trials Register (EudraCT: 2010-023912-14).
RCT Entities:
OBJECTIVE: Statin choice, an encounter decision aid (DA), was developed in the USA to facilitate shared decision making between patients and clinicians about the use of statins to reduce cardiovascular risk. We aimed to assess the efficacy of this DA, compared to usual primary care, in Spanish patients with type 2 diabetes. METHODS: Cluster randomized trial with 29 clinicians and 168 patients. Knowledge of statins, cardiovascular risk perception, decisional conflict, anxiety and satisfaction with the decision making process were assessed immediately after intervention, and self-reported adherence at three months. RESULTS: Intervention significantly improved knowledge (p=0.01), perception of the 10-year risk of myocardial infarction without (p=0.01) and with statins (p=0.08), and satisfaction (p=0.01). There were no significant differences in decisional conflict, anxiety, consultation time or adherence, although more intervention patients reported taking all pills during the last week (92.7% vs. 81%; p=0.19). CONCLUSION: The statin choice DA improved the quality of decision making about statins. PRACTICE IMPLICATIONS: This trial contributes to the body of evidence substantiating the efficacy of statin choice and extending it to Spanish clinicians and their patients with type 2 diabetes. TRIAL REGISTRATION: This trial is registered with the European Union Clinical Trials Register (EudraCT: 2010-023912-14).
Authors: Kunal N Karmali; Stephen D Persell; Pablo Perel; Donald M Lloyd-Jones; Mark A Berendsen; Mark D Huffman Journal: Cochrane Database Syst Rev Date: 2017-03-14
Authors: Claudia Caroline Dobler; Manuel Sanchez; Michael R Gionfriddo; Neri A Alvarez-Villalobos; Naykky Singh Ospina; Gabriela Spencer-Bonilla; Bjorg Thorsteinsdottir; Raed Benkhadra; Patricia J Erwin; Colin P West; Juan P Brito; Mohammad Hassan Murad; Victor M Montori Journal: BMJ Qual Saf Date: 2018-10-09 Impact factor: 7.035
Authors: Elbert S Huang; Aviva G Nathan; Jennifer M Cooper; Sang Mee Lee; Na Shin; Priya M John; William Dale; Nananda F Col; David O Meltzer; Marshall H Chin Journal: Med Decis Making Date: 2016-06-16 Impact factor: 2.583
Authors: France Légaré; Rhéda Adekpedjou; Dawn Stacey; Stéphane Turcotte; Jennifer Kryworuchko; Ian D Graham; Anne Lyddiatt; Mary C Politi; Richard Thomson; Glyn Elwyn; Norbert Donner-Banzhoff Journal: Cochrane Database Syst Rev Date: 2018-07-19
Authors: Lilisbeth Perestelo-Perez; Amado Rivero-Santana; Juan Antonio Sanchez-Afonso; Jeanette Perez-Ramos; Carmen Luisa Castellano-Fuentes; Karen Sepucha; Pedro Serrano-Aguilar Journal: Health Expect Date: 2017-03-10 Impact factor: 3.377
Authors: Thomas H Wieringa; Rene Rodriguez-Gutierrez; Gabriela Spencer-Bonilla; Maartje de Wit; Oscar J Ponce; Manuel F Sanchez-Herrera; Nataly R Espinoza; Yaara Zisman-Ilani; Marleen Kunneman; Linda J Schoonmade; Victor M Montori; Frank J Snoek Journal: Syst Rev Date: 2019-05-20
Authors: Lilisbeth Perestelo-Pérez; Yolanda Álvarez-Pérez; Amado Rivero-Santana; Vanesa Ramos-García; Andrea Duarte-Díaz; Alezandra Torres-Castaño; Ana Toledo-Chávarri; Mario Herrera-Perez; José Luis País-Brito; José Carlos Del Castillo; José Ramón Vázquez; Carola Orrego; Pedro Serrano-Aguilar Journal: Trials Date: 2020-08-24 Impact factor: 2.279